Delving into the Latest Updates on Gonyautoxins(Algenis SpA) with Synapse

Overview

Basic Info

Drug Type

Toxin

Synonyms

PSP NEURO SERUM

Target-

Mechanism-

Therapeutic Areas

Nervous System DiseasesOther Diseases

Active Indication

Chemotherapy-induced damagePeripheral Nervous System DiseasesPoisoning

Inactive Indication

NeuropathySolid tumorSupranuclear Palsy, Progressive

Originator Organization

Algenis SpA

Active Organization

Algenis SpA

Inactive Organization-

Drug Highest PhasePhase 1/2

First Approval Date-

Regulation-

Login to view timeline

Proof-of-concept study to assess the effects of gonyautoxins (PSP NEURO SERUM) on safety and tactile sensitivity on patients with chemotherapy-induced peripheral neuropathy (CIPN). This is a multicenter, prospective proof-of-concept study in patients with solid tumors affected by CIPN. The study will be divided into two parts: Part 1 will assess the activity and tolerability of PSP NEURO SERUM and part 2 consists of a randomized cohort that will compare the activity of PSP NEURO SERUM vs placebo. Part 2 will depend on the results of part 1. If there are less than 8 responses in part 1, the study will be interrupted, and it will not be recommended to proceed with part 2.

Start Date14 Jan 2021

Sponsor / Collaborator

Algenis SpA

[+1]

NCT03025594 / Unknown statusPhase 3

Gonyautoxins Local Periarticular Injection for Pain Management After Total Knee Arthroplasty: A Double Blind Randomized Study

The aim of this study is to demostrate the eficcacy in pain control management after total knee arthroplasty of Gonyautoxin. Local administration during surgery of Gonyautoxin before wound closure can achieved better pain control and lower morphin use during hospital stay compared to local administration of chirocaine, ketorolac and epinephrine

Start Date01 Jan 2017

Sponsor / Collaborator

University of Chile

100 Clinical Results associated with Gonyautoxins(Algenis SpA)

Login to view more data

100 Translational Medicine associated with Gonyautoxins(Algenis SpA)

Login to view more data

100 Patents (Medical) associated with Gonyautoxins(Algenis SpA)

Login to view more data

21

Literatures (Medical) associated with Gonyautoxins(Algenis SpA)

01 Mar 2023·The Journal of Knee SurgeryQ4 · MEDICINE

Gonyautoxins 2/3 Local Periarticular Injection for Pain Management after Total Knee Arthroplasty: A Double-Blind, Randomized Study

Q4 · MEDICINE

Article

Author: Hinzpeter, Jaime ; Campo, Miguel del ; Aliste, Julián ; Catalan, Jaime ; Lagos, Néstor ; Zamorano, Alvaro ; Palet, Miguel ; Barrientos, Cristian ; Barahona, Maximiliano

AbstractThe purpose of this study was to compare the efficacy of periarticular infiltration of gonyautoxin 2/3 (GTX 2/3) and a mixture of levobupivacaine, ketorolac, and epinephrine for pain management after total knee arthroplasty (TKA). Forty-eight patients were randomly allocated to receive periarticular infiltration of 40 µg GTX 2/3 (n = 24) diluted in 30 mL of sodium chloride 0.9% (study group) or a combination of 300 mg of levobupivacaine, 1 mg of epinephrine, and 60 mg ketorolac (n = 24) diluted in 150 mL of sodium chloride 0.9% (control group). Intraoperative anesthetic and surgical techniques were identical for both groups. Postoperatively, all patients received patient-controlled analgesia (morphine bolus of 1 mg; lockout interval of 8 minutes), acetaminophen, and ketoprofen for 72 hours. A blinded investigator recorded morphine consumption, which was the primary outcome. Also, the range of motion (ROM) and static and dynamic pain were assessed at 6, 12, 36, and 60 hours after surgery. The incidence of adverse events, time to readiness for discharge, and length of hospital stay were also recorded. The median of total cumulative morphine consumption was 16 mg (range, 0–62 mg) in the GTX 2/3 group and 9 mg (range, 0–54 mg) in control group, which did not reach statistical difference (median test, p = 0.40). Furthermore, static and dynamic pain scores were similar at all time intervals. GTX 2/3 was inferior in range of motion at 6 and 12 hours; nevertheless, we noted no difference after 36 hours. No differences between groups were found in terms of complications, side effects, or length of hospital stay. No significant differences were found between groups in terms of breakthrough morphine requirement. However, local anesthetic use resulted in an increased ROM in the first 12 hours. This prospective randomized clinical trial shows that GTX 2/3 is a safe and efficient drug for pain control after TKA; nevertheless, more studies using GTX 2/3 with larger populations are needed to confirm the safety profile and efficiency. This is level 1 therapeutic study, randomized, double-blind clinical trial.

01 Jan 2020·ChemosphereQ2 · ENVIRONMENTAL SCIENCE & ECOLOGY

Transcriptomic responses of Artemia salina exposed to an environmentally relevant dose of Alexandrium minutum cells or Gonyautoxin2/3

Q2 · ENVIRONMENTAL SCIENCE & ECOLOGY

Article

Author: Jingjing Zhan ; Xianliang Yi ; Yufeng Gong ; Zhaochuan Li ; Renyan Liu ; Keke Zhang ; Lifen Liu ; Wentao Li ; John P. Giesy

Toxicities of the marine algae Alexandrium minutum and its excreted gonyautoxins (GTXs) to the marine crustacean Artemia salina were investigated. Mortality was observed for neither larvae nor adult A. salina exposed to A. minutum at a density of 5000 cells/mL or 0.5 μM GTX2/3. After exposure, the full transcriptome of adult A. salina was assembled and functionally annotated. A total of 599,286 transcripts were obtained, which were clustered into 515,196 unigenes. Results of the transcriptional effect level index revealed that direct exposure to the toxic algae A. minutum caused greater alterations in the transcriptome than did exposure to the extracellular product GTX2/3. Mechanisms of effects were different between exposure of A. salina to A. minutum cells or GTX2/3. Exposure to A. minutum modulated formation of the ribonucleoprotein complex and metabolism of amino acids and lipids in A. salina. Exposure to GTX2/3 exposure inhibited expression of genes related to metabolism of chitin, which might result in disruption of molting process or disturbed sheath morphogenesis. Overall, effects on transcription observed in this study represent the first report based on application of next generation sequencing techniques to investigate the transcriptomic response of A. salina exposed to an environmentally realistic level of A. minutum or GTX2/3.

01 Sep 2017·Biomedical Chromatography

Development and validation of a high‐throughput online solid‐phase extraction–liquid chromatography–tandem mass spectrometry method for the detection of gonyautoxins 1&4 and gonyautoxins 2&3 in human urine

Article

Author: Coleman, Rebecca ; Lemire, Sharon W. ; Thomas, Jerry ; Garrett, Alaine ; Wharton, Rebekah ; Ojeda‐Torres, Geovannie ; Johnson, Rudolph C. ; Hamelin, Elizabeth ; Bragg, William

AbstractParalytic shellfish toxins (PSTs), including gonyautoxins and saxitoxins, are produced by multiple species of microalgae and dinoflagellates, and are bioaccumulated by shellfish and other animals. Human exposure to PSTs typically occurs through ingestion of recreationally harvested contaminated shellfish and results in nonspecific symptomology. Confirmation of exposure to PSTs has often relied on the measurement of saxitoxin, the most toxic congener; however, gonyautoxins (GTXs), the sulfated carbamate derivatives of saxitoxin, may be present in shellfish at higher concentrations. To improve identification of PST exposures, our group has developed an online solid phase extraction hydrophilic interaction liquid chromatography method to identify GTX1–4 in human urine with tandem mass spectrometry. The reportable range varied for each analyte, with all falling within 0.899 and 250 ng/mL in urine with precision <15% and >85% accuracy as determined for all quality control samples. This new online method quantitates GTX1–4 following exposures to PSTs, supporting the work of public health authorities.

100 Deals associated with Gonyautoxins(Algenis SpA)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chemotherapy-induced damage	Phase 2	BR	Algenis SpA	14 Jan 2021
Peripheral Nervous System Diseases	Phase 2	BR	Algenis SpA	14 Jan 2021
Poisoning	Phase 2	BR	Algenis SpA	14 Jan 2021
Supranuclear Palsy, Progressive	Phase 2	BR	Algenis SpA	14 Jan 2021
Neuropathy	Preclinical	BR	Algenis SpA	14 Jan 2021
Solid tumor	Preclinical	BR	Algenis SpA	14 Jan 2021

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05052398 (ESMO2022) Manual	Phase 1/2	Pneumothorax \| Peripheral Nervous System Diseases	21	Gonyautoxin (secondary to taxanes)	hurrbdmrqb(cztskjngtv) = xaibfgkgbl zdeirsyyaj (qlndfrprgj ) View more	Positive	10 Sep 2022
				Gonyautoxin (secondary to other anti-neoplastic drugs)	hurrbdmrqb(cztskjngtv) = dueehqvvwm zdeirsyyaj (qlndfrprgj ) View more